Pharmaceutical Executive February 20, 2025
Valencia will seek to leverage the investment as well as Surek’s leadership experience to drive commercialization of its flagship eCoin system to develop minimally invasive treatments for urinary incontinence.
Valencia Technologies, a neuromodulation company specializing in minimally invasive treatments for urinary incontinence, has secured a strategic investment of up to $35 million from Brooks Advisory Group. Additionally, the company announced the appointment of James D. Surek as its new CEO. Moving forward, Valencia said that it will take advantage of the investment and Surek’s experience in commercial leadership to drive commercialization of its flagship eCoin system.1
“We are excited to help Valencia Technologies accelerate and scale commercialization of eCoin and continue to carry forward the vision of Jeff Greiner to...
Today's Sponsors
Today's Sponsor